NMTC Relative Valuation
NMTC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NMTC is overvalued; if below, it's undervalued.
Historical Valuation
NeuroOne Medical Technologies Corp (NMTC) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.41. The fair price of NeuroOne Medical Technologies Corp (NMTC) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：0.68
Fair
-4.19
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
NeuroOne Medical Technologies Corp. (NMTC) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -0.88. The thresholds are as follows: Strongly Undervalued below -2.71, Undervalued between -2.71 and -1.80, Fairly Valued between 0.04 and -1.80, Overvalued between 0.04 and 0.96, and Strongly Overvalued above 0.96. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-3.31
EV/EBIT
NeuroOne Medical Technologies Corp. (NMTC) has a current EV/EBIT of -3.31. The 5-year average EV/EBIT is -2.64. The thresholds are as follows: Strongly Undervalued below -6.94, Undervalued between -6.94 and -4.79, Fairly Valued between -0.50 and -4.79, Overvalued between -0.50 and 1.65, and Strongly Overvalued above 1.65. The current Forward EV/EBIT of -3.31 falls within the Historic Trend Line -Fairly Valued range.
3.25
PS
NeuroOne Medical Technologies Corp. (NMTC) has a current PS of 3.25. The 5-year average PS is 100.40. The thresholds are as follows: Strongly Undervalued below -349.94, Undervalued between -349.94 and -124.77, Fairly Valued between 325.57 and -124.77, Overvalued between 325.57 and 550.74, and Strongly Overvalued above 550.74. The current Forward PS of 3.25 falls within the Historic Trend Line -Fairly Valued range.
-6.43
P/OCF
NeuroOne Medical Technologies Corp. (NMTC) has a current P/OCF of -6.43. The 5-year average P/OCF is -3.00. The thresholds are as follows: Strongly Undervalued below -9.97, Undervalued between -9.97 and -6.49, Fairly Valued between 0.49 and -6.49, Overvalued between 0.49 and 3.97, and Strongly Overvalued above 3.97. The current Forward P/OCF of -6.43 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
NeuroOne Medical Technologies Corp. (NMTC) has a current P/FCF of 0.00. The 5-year average P/FCF is -2.74. The thresholds are as follows: Strongly Undervalued below -9.66, Undervalued between -9.66 and -6.20, Fairly Valued between 0.73 and -6.20, Overvalued between 0.73 and 4.19, and Strongly Overvalued above 4.19. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
NeuroOne Medical Technologies Corp (NMTC) has a current Price-to-Book (P/B) ratio of 4.15. Compared to its 3-year average P/B ratio of 8.13 , the current P/B ratio is approximately -48.97% higher. Relative to its 5-year average P/B ratio of 8.44, the current P/B ratio is about -50.85% higher. NeuroOne Medical Technologies Corp (NMTC) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -34.45%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -31.97% , the current FCF yield is about -100.00% lower.
4.09
P/B
Median3y
8.13
Median5y
8.44
-12.00
FCF Yield
Median3y
-34.45
Median5y
-31.97
Competitors Valuation Multiple
The average P/S ratio for NMTC's competitors is 0.00, providing a benchmark for relative valuation. NeuroOne Medical Technologies Corp Corp (NMTC) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 105.39%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of NMTC decreased by 18.76% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 825.78K to 1.70M.
The secondary factor is the P/E Change, contributed -50.55%to the performance.
Overall, the performance of NMTC in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is NeuroOne Medical Technologies Corp (NMTC) currently overvalued or undervalued?
What is NeuroOne Medical Technologies Corp (NMTC) fair value?
How does NMTC's valuation metrics compare to the industry average?
What is the current P/B ratio for NeuroOne Medical Technologies Corp (NMTC) as of Dec 05 2025?
What is the current FCF Yield for NeuroOne Medical Technologies Corp (NMTC) as of Dec 05 2025?
What is the current Forward P/E ratio for NeuroOne Medical Technologies Corp (NMTC) as of Dec 05 2025?